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Abstract
Background:  Emamectin benzoate (EB) is a dominating pharmaceutical drug used for the
treatment and control of infections by sea lice (Lepeophtheirus salmonis) on Atlantic salmon (Salmo
salar L). Fish with an initial mean weight of 132 g were experimentally medicated by a standard
seven-day EB treatment, and the concentrations of drug in liver, muscle and skin were examined.
To investigate how EB affects Atlantic salmon transcription in liver, tissues were assessed by
microarray and qPCR at 7, 14 and 35 days after the initiation of medication.
Results: The pharmacokinetic examination revealed highest EB concentrations in all three tissues
at day 14, seven days after the end of the medication period. Only modest effects were seen on
the transcriptional levels in liver, with small fold-change alterations in transcription throughout the
experimental period. Gene set enrichment analysis (GSEA) indicated that EB treatment induced
oxidative stress at day 7 and inflammation at day 14. The qPCR examinations showed that
medication by EB significantly increased the transcription of both HSP70 and glutathione-S-
transferase (GST) in liver during a period of 35 days, compared to un-treated fish, possibly via
activation of enzymes involved in phase II conjugation of metabolism in the liver.
Conclusion: This study has shown that a standard seven-day EB treatment has only a modest
effect on the transcription of genes in liver of Atlantic salmon. Based on GSEA, the medication
seems to have produced a temporary oxidative stress response that might have affected protein
stability and folding, followed by a secondary inflammatory response.
Background
One of the major problems in aquaculture of salmonids
such as Atlantic salmon (Salmo salar L.) and rainbow trout
(Oncorhynchus mykiss) is production loss due to ectopara-
sites like sea lice [1], which are easily spread between indi-
viduals in densely populated sea cages. The term sea lice is
collectively used for ectoparasitic copepods (Copepoda,
Caligidae) found on marine fish species, including salmo-
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nid fish. The main species of concern in North Atlantic
marine salmonid aquaculture causing infections are
Lepeophtheirus salmonis and Caligus elongatus. The parasites
undergo several developmental stages, including plank-
tonic stages and stages where the parasite is attached to or
moving on the fish surface, feeding on mucus and blood
[2,3]. The main effects of sea lice infestations are general
stress and osmoregulatory problems due to disruption of
the skin by the feeding behaviour of the parasites [4].
Emamectin benzoate (EB) is currently the dominant per-
oral pharmaceutical drug used for the treatment and con-
trol of sea lice infestations on salmonids. EB is commonly
used due to its effectiveness against all stages of sea lice
infection [5]. EB is the active ingredient in SLICE, a com-
mercial drug commonly used for sea lice control in Atlan-
tic salmon farming. It is commonly used in many
countries including Norway, UK, Canada and Chile that
are producing large quantities of Atlantic salmon in aqua-
culture [6]. EB (4''-deoxy-4'' epi-methylamino-avermectin
B1) is a semi-synthetic avermectin, a group of insecticides
that were originally isolated from soil microorganisms [7]
and used for the control of insect pests in edible crops [8].
The mechanism of action of the avermectins in inverte-
brates is the binding to glutamate-gated chloride channels
leading to an influx of chloride ions, thus giving a hyper-
polarized cell. An additional mechanism is increasing the
production of the inhibitory neuro-transmitter GABA at
nerve endings, which prolongs the binding of GABA to
the receptor, thus mediating the same effect. In inverte-
brates, avermectins act on muscle cells and synapses in the
peripheral nervous system, causing paralysis and eventu-
ally death of the parasite. In mammals however, the toxic
effect is low since the avermectins do not cross the mam-
malian blood brain barrier, and thus do not affect GABA-
mediated neurons at in the central nervous system (CNS).
According to the EU legislation described in the directive
EC 2377/90, EB thus has been given a Maximum Residue
Limit (MRL) in edible tissue of 100 ng/g. In fish, the blood
brain barrier is not as impermeable as in mammals and
CNS depression and deaths have been reported in salmon
using avermectin at therapeutic doses.
Orally administered EB is readily absorbed and distrib-
uted to tissues in salmonids [9]. Metabolism of EB in fish
is rather limited, resulting in sustained tissue concentra-
tions. Eventually, absorbed and metabolized EB is
excreted in feces via bile in the liver, a process that proba-
bly involves enterohepatic recirculation of EB, as observed
in SLICE-treated rainbow trout [9]. Possible effects of EB
medication on the fish is therefore most likely to be man-
ifested in hepatocyte cells in the liver, although very little
is known about toxicological effects of EB on salmonid
fishes. Roy et al. [10] examined the tolerance of Atlantic
salmon and rainbow trout to EB exposure, and signs of EB
toxicity included lethargy, dark coloration, inappetance
and loss of coordination but no pathognomonic signs of
toxicity during gross necropsy or histopathological exam-
inations [5]. With the rapidly increasing number of
known gene sequences in many species, transcriptional
analysis has become one of the cornerstones of modern
biology. So far more than 430 000 Atlantic salmon gene
sequences from Atlantic salmon have been deposited in
the Genbank, making it possible to search for biomarkers
based on transcriptional responses to external stimuli
with techniques like qPCR and microarray. The Consor-
tium for Genomic Research on All Salmon Project
(cGRASP) [10]. at the University of Victoria, Canada, has
produced a large-scale cDNA microarray containing about
16000 clones that can be used in search of genome-wide
responses to environmental stressors and medication in
salmonid fishes [11].
The aim of this work was to examine to which degree EB
has a toxic effect or is imposing stress on Atlantic salmon
treated with the anti-salmon lice medication SLICE that
contains EB as the active component. Juvenile Atlantic
salmon were orally administered a daily EB dose of 50 μg/
kg fish, mixed into the feed over a standard seven day
medication period [12]. Tissue residues of EB were meas-
ured in liver, muscle and skin at day 7 (end of the treat-
ment period), 14 and 35. Microarray and qPCR
techniques were used to search for transcriptional biomar-
kers for EB toxicity or stress induction in liver of medi-
cated fish.
Methods
Experimental fish
Juvenile Atlantic salmon (Salmo salar L.) were obtained
from the Institute of Marine Research, Bergen, Norway
and maintained in flow-through seawater tanks (32‰
salinity, mean temperature 9.1°C). Prior to challenge, fish
were randomly assigned to two 500 L tanks and raised in
these throughout the experiment. One group of fish was
kept as a control, whereas the other was treated with EB.
An overview of the experimental design can be seen in Fig.
1.
Fish treatment
The medicated feed was produced by adding EB in a con-
centration of 1 mg/100 g to dry feed. The experimental
fish were administered an oral standard medication
regime of 50 μg EB per kg fish daily for seven days. The
feeding rate was 0.5% body weight per day. Ten individual
fish were collected at time 0 (untreated), thereafter 30
individual fish were collected at day 7, 14 and 35, from
one control (n = 15) and one EB treated group (n = 15) at
each time. A total of 100 fish were used in the experiment.
No mortality was observed throughout the experiment.
On average, the fish weighed 132 ± 21 g at time 0, 147 ±BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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25 g at day 7, 147 ± 27 g at day 14 and 189 ± 28 g at day
35 (mean ± SD). Non-medicated fish were fed a commer-
cial dry pellet salmon feed at 0.5% body weight per day.
The fish were killed by a blow to the head, after being
removed from the tanks. No anesthetics were used.
Tissue sampling
Fish tissues for EB analysis were dissected out and stored
at -20°C before further processing. Approximately 100
mg of tissue was sliced off the liver and immediately flash-
frozen in liquefied nitrogen for RNA extraction. Tissue
specimens for RNA extraction were stored at -80°C before
further processing.
Emamectin benzoate analysis
Fish tissue samples (1.5 g) were homogenized in 1 ml of
0.9% NaCl in water and 300 μl of a solution of 1.5 μg/ml
of ivermectin (internal standard) in methanol. After
homogenization, 6 ml acetonitrile was added followed by
shaking, sonication for 10 min and centrifugation. To the
supernatant, 5 ml n-heptane was added followed by thor-
ough shaking and removal of the n-heptane layer. Water
(20 ml) was then added and the sample was subjected to
solid phase extraction using a OASIS HLB 6 cc cartridge
(Waters Corporation, Milford, Mass. USA) conditioned
with 5 ml methanol followed by 4 ml of distilled water.
After loading the sample, the column was washed with 3
ml of 33% acetonitrile in water and 3 ml of n-heptane
prior to elution of EB by 3 ml of methanol. The column
was dried by vacuum before the final elution of EB. The
eluate was evaporated to dryness under a stream of nitro-
gen using a Reacti-Therm heating unit at 50°C and a
Reacti-Evaporating unit (Pierce, Rockford, IL, USA). The
dry residue was reconstituted in 300 μl methanol and 100
μl n-heptane, shaken for 30 sec and centrifuged for 3 min
at 2000 rpm (Eppendorf 5810 R, Hamburg, Germany).
The methanol fraction was filtered through a 0.45 μm
syringe filter prior to injection into the high performance
liquid chromatographic system (HPLC). Ivermectin and
EB were supplied by Sigma-Aldrich Chemie (Steinheim,
Germany). Methanol, acetonitrile, ammonium-acetate
(all HPLC-grade) and n-heptane, acetic acid (100%; PA-
grade) were all from Merck (Darmstadt, Germany). The
water used was purified with a MilliQ water purification
Experimental design Figure 1
Experimental design. Treatment, sampling and number of fish used for gene transcription analysis. Total number of individuals 
sampled, number of samples used for microarray analysis (MA) and qPCR (PCR) are given for each sampling time. A total of 
100 Atlantic salmon were used in the experiment. RNA was extracted from 70 individuals, 10 from each of the 7 groups. For 
microarray (MA, n = 6) and qPCR verification analysis the same 6 individuals were used; a total of 42 samples were analyzed, 
with 6 biological replicates from each group (3 males and 3 females). For array-independent qPCR analysis of HSP70 and GST, 
n = 10 in each group (total n = 70). EB = Emamectin benzoate.BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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system (Millipore, Bedford, MA, USA). Standards were
made by dissolving 50 mg ivermectin and emamectin in
10 ml of methanol.
The concentration of EB in muscle was determined using
an Agilent 1100 series HPLC connected to a MSD Quad-
ropole mass-spectrometer (Agilent Technologies, Wald-
bronn, Germany). The analytical column was a 125 × 4
mm LiChrosphere C-18, 5 μm with a 4 × 4 mm LiChro-
sphere 100 RP-18, 5 μm guard column (Agilent Technol-
ogies, Palo Alto, CA, USA). The column temperature was
35°C. The mobile phase contained 50 mM ammonium
acetate: acetonitrile: MilliQ water (5:75:20) and the elu-
tion profile was isocratic. The flow rate was 0.8 ml/min,
giving elution times of 9.2 min for EB and 12.1 min for
ivermectin. The injected sample volume was 40 μl. The
mass-spectrometer was tuned in positive selected ion
monitoring (SIM) mode with ion peaks at m/z of 982.5 for
ivermectin and 886.4 for emamectin. The following tune
parameters were used: APCI vaporizer temperature
450°C, corona current 5.0 μA, capillary voltage 2500 V,
nebulizer pressure 60 psi, drying gas 4 l/min and fragmen-
tor voltage 70 V. The calibration curve for emamectin was
prepared in replicate by spiking muscle samples with
standard solutions of emamectin to yield 2.5, 12.5, 25.0
and 50.0 ng/g. Ivermectin (300 ng/g) was added to each
sample and acted as internal standard. The limit of quan-
tification (LOQ) method was determined to be 5.0 ng/g
and the limit of detection (LOD) to be 2.5 ng/g. The
method for detection and quantification of emamectin
used in this study are accredited in accordance with the
international standard ISO/IEC 17025:1999 [13].
RNA extraction
Liver tissues from 70 individuals were thoroughly homog-
enized before RNA extraction with zirconium beads (4
mm) in a MM 301 homogenizer (Retsch GmbH, Haan,
Germany). Total RNA was extracted using Trizol reagent
(Invitrogen, Life Technologies, Carlsbad, CA, USA),
according to the manufacturer's instructions and stored in
50 μl RNase-free MilliQ H2O. Genomic DNA was elimi-
nated from the samples by DNase treatment using DNA-
free according to the manufacturer's description (Ambion,
Austin, TX, USA). The RNA was then stored at -80°C
before further processing. The quality of the RNA was
assessed with the NanoDrop® ND-1000 UV-Vis Spectro-
photometer (NanoDrop Technologies, Wilmington, DE,
USA) and the Agilent 2100 Bioanalyzer (RNA 6000 Nano
LabChip® kit, Agilent Technologies, Palo Alto, CA, USA).
Microarray analysis
A total of 42 RNA samples out of the total of 70 samples
were prepared for microarray analysis. The RIN values for
these 42 samples ranged from 9.3 to 10.0 (mean ± SD: 9.9
± 0.2). RNA was extracted from six fish, three males and
three females, from each group as shown in Fig. 1. cDNA
synthesis was made with the 3DNA Array 350 HS kit
according to the manual (Genisphere Inc., Sterling Drive,
PA, USA). A common reference design was utilized with
the experimental samples in the Cy5 channel and the ref-
erence samples in the Cy3 channel, hybridized to the
cGRASP v.2.0 16 K cDNA microarray [11]. Every 42 sam-
ples, both experimental and control were individually
hybridized with the common reference, with 6 biological
replicates for each group. No technical replicates were run.
Hybridization was performed with a HS 4800 TM Hybrid-
ization station (Tecan, Männedorf, Switzerland), whereas
scanning was performed with a LS Reloaded Scanner
(Tecan, Männedorf, Switzerland). GenePix software
(Axon Instruments, Union City, CA, USA) was used to
analyze the scans. The reference was prepared from a pool
of liver RNA from 50 individuals collected in an inde-
pendent Atlantic salmon experiment.
The data files from GenePix v.5.1 were processed using J-
Express Pro v.2.8 [14] to filter and normalize the hybridi-
zation data and compile the transcription matrix (gene by
sample) for further analysis. The foreground signal inten-
sity values for each channel were extracted for each spot
from the data files according to the GenePix software
manual (Axon Instruments, Union City, CA, USA). All
flagged and control spots were filtered out before the data
were normalized using global lowess [15]. After normali-
zation, weak spots with FG < BG + 1.5*BG_SD in both
channels were filtered out. All arrays were then compiled
into a single expression profile data matrix containing the
normalized log ratios of the two foreground signal inten-
sities. Rows with more than 75% missing values were
removed from the matrix, and the remaining missing val-
ues were estimated using LSimpute_adaptive [16]. Finally
the data was divided into sub-datasets for the individual
sampling days, and genes with at most 25% estimated
missing values were allowed in the final expression
matrix.
The search for differentially expressed genes was per-
formed both on a single gene and gene set level. A two
class paired SAM [17] v.2.1 analysis, as implemented in J-
Express, was used to look for differentially expressed
genes on a gene by gene basis, while GSEA [18,19] also
implemented in J-Express, was used to look for sets of
genes sharing common characteristics that were differen-
tially expressed between the classes examined. Gene sets
were created on the basis of Gene Ontology (Gene Ontol-
ogy Consortium [20]), by mapping the GO annotations
in the cGRASP v.2.0 annotation file (dated August 2007)
to the GO accession numbers in the Gene Ontology OBO
file dated 08.06.07. Parameters of GSEA – Parallel analyses
were run with probes collapsed to genes, using the gene
description column, as well as non-collapsed expressionBMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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matrix as input. Gene sets smaller than 10 and larger than
500 were excluded from the analysis. GSEA was run with
SAM score as the ranking statistic. Significance of the gene
set analysis was tested by permuting the scores over the
genes (10000 iterations).
qPCR
In order to verify the microarray data, qPCR was used to
quantify the transcriptional levels of eight differentially
regulated genes in the same 42 RNA samples as used for
microarray analysis. For verification, genes were picked
from the statistical analysis of microarray (SAM) lists; two
up-regulated and one down-regulated genes based on q-
statistics [GenBank:CB511007;CB509633;CB514814],
and one up-regulated and three down-regulated genes
based on fold-change [GenBank:CA056074;CB488966;
CA053315;CB491960]. In addition, one gene was picked
that appeared to be un-regulated but was included in sev-
eral gene sets (HLA class II histocompatibility antigen,
gamma chain [GenBank:CK990815]. qPCR assays were
designed using Primer Express 2.0 software (Applied Bio-
systems, Foster City, CA, USA) to select appropriate
primer sequences from gene sequences included on the
array. Since some of the primers did not span exon-exon
borders, all RNA samples were subjected to DNase treat-
ment to avoid genomic DNA contamination. PCR primer
sequences, GenBank accession numbers and amplicon
lengths of the genes selected for qPCR verification are
shown in Table 1.
A two-step qPCR protocol was developed to measure the
mRNA levels of the eight target genes and the three refer-
ence genes (β-actin, elongation factor 1AB (EF1AB) and
acidic ribosomal protein (ARP)) in liver tissue of Atlantic
salmon. The reverse transcription reactions were run in
duplicate on 96-well reaction plates with the GeneAmp
Table 1: PCR primers and TaqMan MGB probes, Genbank accession numbers, amplicon sizes and fold changes (microarray and qPCR 
verification) for the studied genes.
Gene Accession no. Forward primer 
(5'-3')
Reverse primer 
(5'-3')
TaqMan MGB 
probe
Amplicon size 
(bp)
Microarray qPCR
Thrombospondin 4 
precursor Day 14
CB509633 GCAGCGGTACTT
TAGGTTGGA
ATCAGGGCCCG
TTTCTATGA
141 -1.6 -1.7
Purine nucleoside 
phosphorylase Day 
14*
CB514814 GCCCCCTTCATG
GGTACAC
AACGCCTGAAC
GAACGAATG
135 2.1 1.6
CYP2B19 Day 7 CA053315 AGCCTGTGACCT
CTCCACAGTAA
CGGCACAAAAC
CTCCAGAAG
134 -3.2 -2.2
CYP2A5 Day 7 CB491960 AGGTTTGGTGCC
GGTGAAA
ATGATGGATTCT
TTGCTTTTGGA
125 -3.2 -1.7
Low affinity 
immunoglobulin 
epsilon Fc receptor 
Day 14*
CB511007 CCACTCACAGG
GCACATCAA
GTGGTCAGATG
GGTCCAGATTT
133 2.8 2.1
NADH-ubiquinone 
oxireductase chain 1 
Day 7
CB488966 GGCCGGCACGA
GTAGTCA
GGCAGTGGCAC
AAACCATTT
133 -3.3 -1.2
Sequestosome-1 
Day 14*
CA056074 GGGACAGAAAG
AGAAGGCAGTAT
T
GCCCTGGACAC
CATCCACTA
131 1.3 1.1
HLA class II 
histocompatibility 
antigen, gamma 
chain Day 14*
CK990815 TTATATGCTGTC
CGAAGGCAAA
CCCTCCCCCAA
AAAATACACA
141 1.1 1.2
Heat shock protein 
70
AJ632154 TCAACGATCAGG
TCGTGCAA
CGTCGCTGACC
ACCTTGAA
CCGACATGAA
GCACTGG
141
Glutathione S-
transferase pi
BQ036247 ATTTTGGGACGG
GCTGACA
CCTGGTGCTCT
GCTCCAGTT
TTCTCGACAAA
GCTC
81
β-actin BG933897 CCAAAGCCAACA
GGGAGAAG
AGGGACAACAC
TGCCTGGAT
TGACCCAGATC
ATGTTT
91
EF1AB BG933853 TGCCCCTCCAG
GATGTCTAC
CACGGCCCACA
GGTACTG
CCAATACCGC
CGATTTT
59
ARP AY255630 TCATCCAATTGC
TGGATGACTATC
CTTCCCACGCA
AGGACAGA
CAAATGTTTCA
TTGTCGGCG
101
* = up-regulated genesBMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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PCR 9700 machine (Applied Biosystems) using TaqMan
Reverse Transcription Reagent containing Multiscribe
Reverse Transcriptase (50 U/μl) (Applied Biosystems).
Twofold serial dilutions of total RNA were made for effi-
ciency calculations. Five serial dilutions (1000 – 63 ng) in
triplicates were analyzed by qPCR in separate sample
wells and the resulting crossing thresholds (Cts) recorded.
Total RNA input was 500 ng in each reaction for all genes.
No template control (ntc) and RT-control (a duplicate
RNA sample analysis where only the RT enzyme is left
out) reactions were run for quality assessment. RT-con-
trols were not performed for every individual sample, but
were run for each assay or gene, with the same sample as
used to make the dilution curves on the 96 well plates.
Reverse transcription was performed at 48°C for 60 min
by using oligo dT primers (2.5 μM) for all genes in 30 μl
total volume. The final concentration of the other chemi-
cals in each RT reaction was: MgCl2 (5.5 mM), dNTP (500
mM of each), TaqMan RT buffer (1×), RNase inhibitor
(0.4 U/μl) and Multiscribe reverse transcriptase (1.67 U/
μl).
2.0 μl cDNA from each RT reaction for all genes was trans-
ferred to a new 96-well reaction plate and the qPCR run in
20 μl reactions on the LightCycler® 480 Real-Time PCR
System (Roche Applied Sciences, Basel, Switzerland).
qPCR was performed by using SYBR Green Master Mix
(LightCycler 480 SYBR Green master mix kit; Roche
Applied Sciences), which contains FastStart DNA
polymerase and gene-specific primers (500 nM each).
PCR was achieved with initial denaturation and enzyme
activation for 5 min at 95°C, followed by 40 cycles of 10
s denaturation at 95°C, 20 s annealing at 60°C and 30 s
elongation at 72°C. The geNorm VBA applet for Microsoft
Excel was used to determine a normalization factor from
the three examined reference genes used to calculate mean
normalized expression (MNE) for ACTB, EF1AB and ARP.
The Ct values were transformed to quantities using stand-
ard curves, according to the geNorm manual [21]. geNorm
determines the individual stability of a gene within a pool
of genes, and calculates the stability according to the sim-
ilarity of their transcription profile by pair-wise compari-
son, using the geometric mean as a normalizing factor.
The gene with the highest M, i.e. the least stable gene, is
then excluded in a stepwise fashion until the most stable
genes are determined. Here a normalizing factor based on
all three examined reference genes was used to calculate
the MNE.
Independent and a priori of the microarray analysis, the
transcriptional levels of two additional genes that were
assumed to be affected by the EB treatment were quanti-
fied by qPCR. In this examination, mRNA levels were
quantified in 10 individuals from each group, as opposed
to n = 6 in the microarray and subsequent qPCR verifica-
tion analysis. The PCR primers and probes used to quan-
tify these transcripts were based on Genbank sequences
not included on the cGRASP array. PCR primer sequences
used for quantification of the genes encoding β-actin,
EF1AB and ARP, used as reference genes, and HSP70 and
GST π, were based on the following Genbank accession
numbers [GenBank:BG933897;BG933853;AY255630;AJ
632154;BQ036247], respectively. TaqMan 3'-Minor
groove binder-DNA (MGB) probes were used to quantify
these genes as described by Olsvik et al. [22]. Analyzed
with geNorm [21], EF1AB was found to be the most stable
reference gene, and therefore used to calculate mean nor-
malized expression with the qGene tool [23]. Except for
the β-actin and EF1AB assays, the PCR primers or probes
did not span exon-exon borders. All RNA samples were
therefore treated with DNase (Ambion) according to the
manufacturers instructions. Amplified PCR products were
sequenced as described above and subsequently com-
pared to the database using BLAST to ensure that the cor-
rect mRNAs were analyzed.
Statistics
The GraphPad Prism 4.0 (GraphPad Software, Inc., San
Diego, CA, USA) and J-Express Pro (Molmine, Bergen,
Norway) software were used for the statistical analyses in
this work. Linear regression and correlation analysis were
performed with GraphPad Prism, whereas significance of
microarray (SAM) and gene set enrichment analysis
(GSEA) were performed with J-Express Pro. A wide range
of statistics can be used to calculate differential transcrip-
tion between two groups. T-test and S-score (regularized t-
score) that is used in SAM [17] are commonly used tests.
SAM was used here because it is well adapted to microar-
rays and reports q-values for assessment of statistical sig-
nificance of the results after correcting for multiple testing.
Gene set enrichment analysis (GSEA) calculates an enrich-
ment score (ES) for a given gene set using rank of genes
and infers statistical significance of each ES against ES
background distribution calculated by permutation of the
original data set [18,24]. For qPCR validation an alpha
level of 0.05 was considered significant, while for SAM
and GSEA a threshold of 10% false discovery rate was used
to control for multiple testing in the genome wide data
analysis.
Results
Pharmacokinetics
The concentrations of EB in liver, muscle and skin at days
7, 14 and 35 after the initiation of emamectin benzoate
medication are shown in Fig. 2. At day 7 the mean concen-
tration of EB in samples of liver was 33 ng/g, whereas the
mean concentrations in muscle were 1 ng/g. The skin did
not contain EB in concentrations above the level of detec-
tion (LOD) at day 7. At day 14 the mean concentrations
in liver, muscle and skin were 9002, 81 and 369 ng/g,BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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Pharmacokinetics Figure 2
Pharmacokinetics. Uptake and drug residues of EB in Atlantic salmon, (Salmo salar L.), administered a standard daily oral dose 
of 50 μg/kg for 7 days (mean ± SEM). The levels of EB were quantified in 6 individuals in liver (the same individuals as used for 
microarray analysis) and 15 individuals in muscle and skin tissues. <DL: below detection limit.BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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respectively. The corresponding mean concentrations at
day 35 were 4902, 34 and 258 ng/g respectively. Overall,
the EB concentrations were highest at day 14, and had
dropped by day 35.
Gene expression profiling data
The microarray data revealed only small alterations in
transcript levels in the EB-medicated fish compared to the
control at day 7, 14 and 35. The SAM analysis showed that
only three genes were significantly differentially expressed
at day 7; type IV antifreeze protein precursor, MHC class I
antigen alpha chain BL3-7 and an unknown gene. At day
14 only two genes displayed differential transcription lev-
els, thrombospondin-4 precursor and purine nucleoside
phosphorylase. Correspondence analysis (CA) is used to
look for the greatest co-variances (between samples and
genes) in the data. The plot gives a global view of the data
and can reveal clustering of samples according to their
biological groups. At day 7, the CA plot showed that there
is a tendency of separation of the EB-medicated and the
control groups (Fig. 3A). Since the pharmacokinetic meas-
urements reveal the highest EB concentration in the liver
at day 14, we expected to see more differences between the
two groups at this time point. Although it was not possi-
ble to draw a straight line between the points to separate
the two groups, the CA plot clearly showed a tendency of
separation between the two groups at day 14 (Fig. 3B). On
the contrary, there did not seem to be major differences
between the two groups on day 35 based on the global CA
plot. The microarray data has been submitted to ArrayEx-
press with MIAME required documentation and is availa-
ble under the accession number E-BASE-9.
Gene set enrichment analysis
The overall effects of EB treatment on hepatic transcrip-
tional levels were modest, which may have reduced the
significance of biologically relevant genes because their
signal intensities were relatively low. It was therefore
decided to evaluate the data using the newest Gene Ontol-
ogy annotations of the arrayed probes to identify signifi-
cant biological changes. Table 2 shows gene sets up-
regulated at day 7, ordered by the normalized enrichment
score, with a false discovery rate (FDR) cutoff of approxi-
mately 10%, meaning that we expected a maximum of 1
out of 10 gene sets to be false positives. Probes annotated
to the same gene were not collapsed before performing
GSEA that resulted in the FDR values shown in Table 2.
Multiple probes on the array mapped to the same gene in
a gene set will produce more significant FDR values, but
as long as the Atlantic salmon genome is relatively poorly
annotated, i.e. with unknown gene function, isoforms
and splice variants, this strategy was selected in order not
to lose valuable biological information. By collapsing
data at the level of gene symbols, one risks an unintended
merging of information from every pair of paralogue
genes in the salmon genome. On the other hand, by not
collapsing the data, one risks the pitfall of some gene sets
being favored in the statistical calculation due to several
probes for the same gene contributing to a particular gene
set. A similar biological picture of inflammation and oxi-
dative stress was also seen in the collapsed data set, but
not at the same 10% FDR level of significance. Up-regu-
lated gene sets at day 14 are shown in Table 3. No gene
sets were significantly down-regulated at day 7 or at day
14. Table 4 shows up- and down-regulated gene sets at day
35, again with a FDR cutoff of approximately 10%.
qPCR verification
The qPCR results supported the microarray data (Table 1),
with differences only in the scale of estimated up-regula-
tion or down-regulation. Even with the small fold changes
in transcriptional levels observed in this experiment there
was a significant correlation between the microarray and
the qPCR data (Pearson correlation, r2 = 0.92, P < 0.0001;
Fig. 4).
Independent of the microarray data, the transcriptional
levels of two genes encoding stress-responsive proteins
were quantified. HSP70 and GST are both well known to
respond to external stress in animals, and have often been
used as biomarkers. At day 7, the transcriptional levels of
both HSP70 (2-way ANOVA, P < 0.01) and GST (2-way
ANOVA, P < 0.05) were higher in the control group com-
pared to the EB-treated group (Fig. 5A and 5B). No signif-
icant differences were seen at day 14, whereas both genes
showed significantly higher mRNA levels at 35 day in the
EB-treated groups compared to the control groups (2-way
ANOVA; HSP70, P < 0.05, GST, P < 0.01).
Discussion
Very few genes were significantly differentially regulated
in liver (the major detoxifying organ) of EB-medicated
fish compared to the control fish at the end of the medi-
cation period (day 7), seven days after the end of medica-
tion (day 14) and 28 days after the end of the medication
(day 35), analyzed by a two class unpaired SAM analysis.
Only small fold-change alterations were found in liver,
less than two for most of the genes. The results suggest
that a standard seven-day treatment with orally adminis-
tered EB during sea lice treatment (50 μg/kg fish) has only
modest physiological impacts on Atlantic salmon.
According to EU legislation the Maximum residue limit
(MRL) for EB in fish products for human consumption is
100 ng/g. In all examined tissues the highest EB levels
were measured at day 14, seven days after the end of the
treatment period. Even at this time point, the EB levels in
muscle were below the MRL, suggesting that filet, with the
skin removed, is within accepted limits throughout the
medication period. The liver in particular, accumulatedBMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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Correspondence analysis (CA) of arrays after day 7 (A) and day 14 (B) Figure 3
Correspondence analysis (CA) of arrays after day 7 (A) and day 14 (B). C = controls, E = EB-treated. n = 6, except in the con-
trol group at day 7 (n = 4) and the control group at day 14 (n = 5).BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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much higher amounts of EB; at day 14 the level was 9002
ng/g, whereas the concentration in skin was 369 ng/g.
These concentrations are in line with earlier published
results from examinations of EB-treated Atlantic salmon
[9,12]. In a distribution study, Sevatdal et al. [12] reported
the highest concentrations in excretory organs, liver and
kidney, using autoradiography. High activity in bile sug-
gested that this is the major excretory route. In contrast to
our results, they found the highest quantity in liver at Day
7, the last day of administration, whereas in kidney the
highest quantities were seen at day 28. Their experiment
was performed at higher ambient water temperatures
(15–19°C) as compared to the temperature applied in our
study (9°C). This may explain the slower distribution of
EB to the liver in our experiment. Our results clearly show
that EB is easily accumulated in liver of Atlantic salmon
and that residues remain in this organ for many weeks.
Potential transcriptional effects of EB administration in
the fish should therefore most likely be seen in the liver at
the end of the medication period or seven days after the
end of the treatment.
Table 2: Gene sets significantly up-regulated after 7 days of medication (day 7).
Rank Gene Sets – Up-regulated Size Nom P-value FDR (%)
1 Protein disulfide isomerase activity 26 0.0 1.72
2 Intramolecular oxidoreductase activity, transposing S-S bonds 26 0.0 0.86
3 Peptidyl-asparagine modification 16 0.0 3.2
4 Protein amino acid N-linked glycosylation via asparagine 16 0.0 2.4
5 Intramolecular oxidoreductase activity 36 0.0 2.89
6 Protein localization 37 0.0 11.7
7 Isomerase activity 52 0.0 10.9
8 Peptidyl-amino acid modification 23 0.0 10.79
9 Oligosaccharyl transferase complex 19 0.0 10.66
Gene set enrichment analysis (GSEA) with a false discovery rate (FDR) cut-off of approximately 10%. Nominal P values are also shown, as well as 
gene set sizes (number of genes in each gene set). No gene sets were significantly down-regulated after 7 days of medication, with a FDR lower than 
about 10%.
Table 3: Gene sets significantly up-regulated 7 days after the end of the medication period (day 14).
Rank Gene Sets – Up-regulated Size Nom P-value FDR (%)
1 Prostanoid biosynthetic process 19 0.0 0.38
2 Prostaglandin biosynthetic process 19 0.0 0.19
3 Cytokine binding 21 0.0 0.37
4 Regulation of macrophage activation 15 0.0 0.44
5 Ecosanoid biosynthetic process 29 0.0 0.49
6 Ecosanoid metabolic process 29 0.0 0.41
7 Carbohydrate binding 34 0.0 0.47
8 Macrophage activation 18 0.0 0.6
9 Myeloid leukocyte activation 18 0.0 0.54
10 Sugar binding 29 0.0 0.98
11 Monosaccharide binding 16 0.0 1.79
12 Glutamate dehydrogenase [NAD(P)+] activity 14 0.0 2.99
13 Leukocyte activation 37 0.0 3.58
14 Activation of MAPK activity 12 0.0 4.6
15 Intracellular protein transport 41 0.0 5.8
16 Protein amino acid N-linked glycosylation via asparagines 17 0.0 5.94
17 Peptidyl-asparagine modification 17 0.0 5.59
18 Oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor 17 0.0 5.54
19 Mannose binding 12 0.01 5.34
20 Antigen processing and presentation of exogenous peptide antigen via MHC class II 24 0.0 8.97
21 Antigen processing and presentation of peptide antigen via MHC class II 24 0.0 8.55
22 Transition metal ion binding 31 0.0 8.69
23 Peptidyl-amino acid modification 24 0.01 10.94
Gene set enrichment analysis (GSEA) with a false discovery rate (FDR) cut-off of approximately 10%. Nominal P values are also shown, as well as 
gene set sizes (number of genes in each gene set). No gene sets were significantly down-regulated 7 days after the end of the medication period, 
with a FDR lower than about 10%.BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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Gene set enrichment analysis (GSEA) is an analysis
method that evaluates the expression of biological path-
ways on a priori defined gene sets, e.g. biological path-
ways, rather than looking at individual genes, to identify
significant biological changes in microarray data sets [18].
GSEA is therefore especially useful when the transcrip-
tional changes in a given microarray data set are minimal
or moderate. GSEA has been applied widely as a tool for
gene-set analysis using Gene Ontology (GO) terms. Atlan-
tic salmon is currently not covered by the Gene Ontology
Consortium. However GO information is included in the
cGrasp annotation file, which contains annotations as of
August 2007.
At the end of the medication period (Day 7), nine gene
sets were found to be up-regulated (FDR level of 10%) in
the treatment group compared to the control group. Six of
these gene sets consist of genes encoding proteins
involved in protein folding, i.e. isomerase and oxidore-
ductase activities, partly overlapping between the various
gene sets. These proteins can also act as chaperones. Pro-
tein disulfide isomerase activity (molecular function:
GO:0003756) ranked number one. Among the proteins
ranked in these seven gene sets are protein disulfide iso-
merase precursors (PDI) A2 (PDIA2), A3 (PDIA3) and A6
(PDIA6), sequestosome-1 (Sqstm-1), PDI prolyl 4-
hydroxylase subunit beta (P4HB), arginyl-tRNA syn-
thetase (RARS), prostaglandin E synthase 3 (PTGES3),
Table 4: Gene sets significantly up-regulated or down-regulated 28 days after the end of the medication period (day 35).
Rank Gene Sets – Up-regulated Size Nom P-value FDR (%)
Up-regulated
1 Protein dimerization activity 60 0.0 3.72
2 Second-messenger-mediated signaling 20 0.0 1.86
3 Endonuclease activity 21 0.0 3.31
4 Protein heterodimerization activity 29 0.0 4.75
5 mRNA catabolic process 20 0.0 4.74
6 mRNA catabolic process, nonsense-mediated decay 17 0.0 6.18
7 Endonuclease activity, active with either ribo- or deoxyribonucleic
acids and producing 5'-phosphomonoesters 19 0.0 9.22
8 Endoribonuclease activity, producing 5'-phosphomonoesters 19 0.0 8.07
9 Phosphoprotein phosphatase activity 22 0.0 7.2
Down-regulated
1 Nucleobase, nucleoside, nucleotide kinase activity 25 0.0 0.09
2 Telomerase holoenzyme complex 24 0.0 0.66
3 Prostaglandin biosynthetic process 18 0.0 2.04
4 Prostanoid biosynthetic process 18 0.0 1.53
5 Kinase activity 41 0.0 1.33
6 Nucleotide kinase activity 12 0.0 1.63
7 Kinase regulator activity 11 0.0 2.65
8 Pigment granule 15 0.0 6.8
9 Melanosome 15 0.0 6.04
10 Peptide antigen transport 10 0.0 9.18
Nominal P values are shown, as well as gene set sizes (number of genes in each gene set). Gene set enrichment analysis (GSEA) with a false 
discovery rate (FDR) cut-off of approximately 10%.
qPCR verification Figure 4
qPCR verification. Linear correlation between microarray 
and qPCR fold changes. Pur: puridine nucleoside phosphory-
lase, HLA: HLA class II histocompatibility antogen, gamma 
chain, Seq: sequestosome, Thromb: thrombospondin 4 pre-
cursor, LAIE Fc r: low-affinity immunoglobulin epsilon Fc 
receptor, NADH: NADH ubiquinone oxireductase chain 1, 
CYP2A5: cytochrome P450 2A5, CYP2B19; cytochrome 
P450 2B19.BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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phosphoglycerate mutase 1 (PGAM1), ADP-ribosylation
factor GTPase activating protein 3 (ARFGAP3) and arfap-
tin-1 (ARFIP1). Also included in the top gene set is
CYP1A, the major phase I enzyme in the cytochrome
P450 system, an enzyme regulated by a number of physi-
ological conditions and xenobiotics. The CYP system is a
central catalyst of oxidative reactions including hydroxyla-
tion, epoxidation and dealkylation. Although the consti-
tutive level of CYP1A in fish is low, several factors,
exogenous as well as endogenous, can affect the CYP1A
expression in fish [25]. The major phase I metabolic path-
way of ivermectin and EB in rainbow trout and Atlantic
salmon is demethylation [9,26]. This may explain the
induction of the CYP1A system found in this study. Pro-
tein disulfide isomerases are endoplasmic reticulum (ER)
resident proteins that catalyze the formation, reduction,
and isomerization of disulfide bonds in proteins and are
thought to play a role in folding of disulfide-bonded pro-
teins [27]. The majority of disulfide-linked cytosolic pro-
teins are thought to be enzymes that transiently form
disulfide bonds while catalyzing redox processes. Cum-
ming et al. [28] recently showed that reactive oxygen spe-
cies (ROS) can act as signaling molecules by promoting
the formation of disulfide bonds within or between
redox-sensitive proteins. Our results suggest that EB treat-
ment may have mediated oxidative stress in the liver, a
finding, however, not supported by the levels of HSP70
mRNA at Day 7 (quantified by qPCR, Fig. 5A). On the
contrary, HSP70 mRNA expression was significantly
higher in the control group at day 7, indicating that the
control fish might have been stressed during the first 7
days of the experiment. Only at day 35 was the HSP70
mRNA level significantly higher in the medicated group.
Heat shock proteins are a family of highly conserved pro-
teins that protect the cells against cytotoxic effects of pro-
tein degradation [29]. Many types of external stress can
induce HSPs in fish, including oxidative stress [30,31],
even though their value as biomarkers of various form of
stress in fish has been questioned [32]. Judged by the
enriched gene sets at day 35, oxidative stress seems to have
been a transient response, since none of these gene sets
contained HSPs.
Neither GST π showed increased transcriptional levels at
day 7 (Fig. 5B); only at day 35 was the transcriptional level
of GST significantly higher in the EB-treated group com-
pared to the control group. The GSTs are a family of
biotransforming enzymes that protect cells against injury
from a number of endogenous and environmental chem-
icals. Trute et al. [33] characterized GSTs in Coho salmon
(Oncorhynchus kisutch). They found two major GST iso-
forms in liver, the π and θ-class GSTs, but noted that they
might have a limited capacity to conjugate substrates of
various toxicants and endogenous compounds associated
with cellular oxidative stress. We have recently shown that
the GST π class is inducible by β-naphthoflavone in Atlan-
tic salmon [34]. The results presented here suggest that
that the π class GST is inducible by EB in Atlantic salmon
and that EB may undergo glutathione conjugation. This
metabolite has however not yet been described in fish.
The other three gene sets up-regulated at Day 7 in the EB-
medicated fish consist of genes encoding proteins
involved in protein modification processes
(GO:0006464), i.e. peptidyl-asparagine modification
[GO:0018196]. Proteins encoded by genes in these gene
sets include among others dolichyl-diphosphooligosac-
charide-protein glycosyltransferase (defender against cell
death 1, DAD1) and various DAD1 subunits, keratinoc-
yte-associated protein 2 (KRTCAP2), strumpellin
(KIAA0196), alpha-1,6-mannosyl-glycoprotein 2-beta-N-
acetylglucosaminyltransferase (Mgat2), arginine/serine-
rich coiled coil protein 1 (RSRC1) and cytochrome c oxi-
dase subunit-1 (MT-CO1). DAD1 was initially identified
Mean normalized expression (MNE) of A) HSP70 and B) GST  in liver of Atlantic salmon (Salmo salar L.) orally medicated  with the anti-salmon louse medicine SLICE (that contains  50% EB) for 7 days (mean ± SEM.) Figure 5
Mean normalized expression (MNE) of A) HSP70 and B) GST 
in liver of Atlantic salmon (Salmo salar L.) orally medicated 
with the anti-salmon louse medicine SLICE (that contains 
50% EB) for 7 days (mean ± SEM.). Samples were taken at 
day 0 (start of administration), day 7 (end of oral administra-
tion), day 14 and day 35. Analyzed by 2-way ANOVA. Over-
all ANOVA P-value shown in each graph. Significant 
differences at each time-point are also shown in the graphs. n 
= 10 in all groups except control day 35 where n = 7.BMC Pharmacology 2008, 8:16 http://www.biomedcentral.com/1471-2210/8/16
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as a negative regulator of apoptosis in the BHK21-derived
tsBN7 cell line, and is a subunit of the mammalian oli-
gosaccharyltransferase [35]. It has been shown that loss of
the DAD1 protein triggers apoptosis [35]. The throm-
bospondin-4 precursor (THBS4), belonging to the throm-
bospondin family, a group of proteins involved in the
positive regulation of apoptosis, was significantly down-
regulated at day 7, verified by qPCR analysis. These find-
ings suggest that EB treatment may have affected the regu-
lation of apoptosis. Although involved in a number of
biological processes, the proteins encoded by the genes
comprising these two pathways, suggest that EB treatment
might have affected protein stability and folding at day 7,
possible via induced oxidative stress.
The most significant up-regulated gene sets at day 14 sug-
gest that EB treatment induced an inflammatory response
(prostaglandin biosynthetic process GO:0001516) in the
liver. Proteins encoded by genes in the top six gene sets
include prostaglandin E synthase 3 (PTGES3), HLA class
II histocompatibility antigen gamma chain (CD74), H-2
class II histocompatibility antigen gamma chain (Cd74),
H-2 class II histocompatibility antigen, A-B alpha chain
precursor (H2-Aa), fibrinogen gamma chain precursor
(Fqq), myosin-9 (Myh9), hematopoietic SH2 domain-
containing protein (Hsh2d), zinc finger protein 706
(ZFP706) and 15-hydroxyprostaglandin dehydrogenase
(NAD+) (Hpgd). Prostanoids, including eicosanoids and
metabolites of eicosapolyenoic fatty acids, are not stored
by cells but rather synthesized in many cell types in
response to cell-specific proteolytic or hormonal stimuli
[36]. These processes are usually receptor-mediated, but
may also be elicited by mechanical stresses on cells [36].
Up-regulation of prostanoids further suggests that EB
treatment mediated oxidative stress, as free radicals may
oxidize unsaturated fatty acids [37], i.e. eicosanoids. Sur-
prisingly, the prostanoid pathways were down-regulated
at day 35, suggesting a counter-reaction in gene transcrip-
tion.
Several gene sets were differentially changed at day 35,
indicating that EB still affected transcription in hepatic
cells one month after the end of the medication period.
Protein dimerization activity (GO:0046983) was listed as
the most up-regulated gene set. Also up-regulated was
endonuclease activity (GO:0048256). These findings sug-
gest that EB treatment affected protein binding and nucle-
otide cleavage even at day 35, although further
examinations are needed in order to elucidate to long-
term effects of EB medication in salmon.
qPCR is a commonly used validation tool for microarray
analysis. Microarray and qPCR data often disagree, and no
standard definition for validation exists [38]. It is well
documented that both qPCR and microarray analysis
have inherent pitfalls that may influence transcriptional
levels quantified with each method. In this work we
picked 8 of the most significant genes from the SAM anal-
ysis for qPCR verification, of which most were changed
less than 2-fold. The qPCR data were in line with the array
data, although the down-regulated genes showed higher
discrepancy than the up-regulated genes, for an unknown
reason.
Conclusion
In conclusion, this study has shown that a standard seven-
day EB treatment has only modest effects on the transcrip-
tion of genes in liver of Atlantic salmon. Based on GSEA,
the medication seems to have produced a temporary oxi-
dative stress response that appeared to affect protein sta-
bility and folding, followed by a secondary inflammation.
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